The genetics of haemostasis: a twin study
暂无分享,去创建一个
T. Spector | H. Snieder | P. Grant | R. Ariëns | M. D. Lange
[1] J. Weisel,et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. , 2000, Blood.
[2] T. Spector,et al. Twins. Novel uses to study complex traits and genetic diseases. , 2000, Trends in genetics : TIG.
[3] P. Grant,et al. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. , 2000, Blood.
[4] M Farrall,et al. Genetic influences on F cells and other hematologic variables: a twin heritability study. , 2000, Blood.
[5] P. Grant,et al. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking, and hypertension. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[6] D. Lillicrap,et al. Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF :Ag levels : Identification of three novel single nucleotide polymorphisms in the vWF gene promoter , 1999 .
[7] P. Grant,et al. FXII (46C→T) Polymorphism and In Vivo Generation of FXII Activity , 1999, Thrombosis and Haemostasis.
[8] Yuling Hong,et al. Genetic Effects for Plasma Factor VII Levels Independent of and in Common with Triglycerides , 1999, Thrombosis and Haemostasis.
[9] S. Vettore,et al. Determinants of plasma levels of plasminogen activator inhibitor-1 : A study of normotensive twins. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[10] P. Grant,et al. A Common Coding Polymorphism in the FXIII A-subunit Gene (FXIIIVAL34LEU) Affects Cross-linking Activity , 1998, Thrombosis and Haemostasis.
[11] M. Laffan,et al. Analysis of the F8 Gene in Individuals with High Plasma Factor VIII:C Levels and Associated Venous Thrombosis , 1998, Thrombosis and Haemostasis.
[12] G. Siest,et al. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[13] P. Elwood,et al. Fibrin D-dimer, Tissue Plasminogen Activator, Plasminogen Activator Inhibitor, and the Risk of Major Ischaemic Heart Disease in the Caerphilly Study , 1998, Thrombosis and Haemostasis.
[14] A. Carter,et al. Levels of Activated FXII in Survivors of Myocardial Infarction – Association with Circulating Risk Factors and Extent of Coronary Artery Disease , 1998, Thrombosis and Haemostasis.
[15] U. de Faire,et al. Moderate genetic influences on plasma levels of plasminogen activator inhibitor-1 and evidence of genetic and environmental influences shared by plasminogen activator inhibitor-1, triglycerides, and body mass index. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[16] J. Barrett,et al. von Willebrand Factor and Factor VIII: C in Acute Cerebrovascular Disease , 1997, Thrombosis and Haemostasis.
[17] D. Arveiler,et al. Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[18] D. Ginsburg,et al. Von Willebrand disease. , 2008, Pediatric clinics of North America.
[19] N. Ossei-Gerning,et al. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[20] M. Pinotti,et al. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[21] S. Humphries,et al. The 4G/5G Genetic Polymorphism in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene Is Associated with Differences in Plasma PAI-1 Activity but not with Risk of Myocardial Infarction in the ECTIM Study , 1995, Thrombosis and Haemostasis.
[22] Y. Friedlander,et al. Genetic and environmental sources of fibrinogen variability in Israeli families: the Kibbutzim Family Study. , 1995, American journal of human genetics.
[23] L. Berkman,et al. Genetic susceptibility to death from coronary heart disease in a study of twins. , 1994, The New England journal of medicine.
[24] P. Ridker,et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction , 1993, The Lancet.
[25] D. Barker,et al. Relation of fetal and infant growth to plasma fibrinogen and factor VII concentrations in adult life. , 1992, BMJ.
[26] W. Kannel,et al. Coronary risk associated with age and sex of parental heart disease in the Framingham Study. , 1989, The American journal of cardiology.
[27] M. Blombäck,et al. GENETIC AND CULTURAL INHERITANCE OF PLASMA FIBRINOGEN CONCENTRATION , 1987, The Lancet.
[28] R. D'Agostino,et al. Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.
[29] M. Blombäck,et al. PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.
[30] S. Thompson,et al. HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.
[31] P. Magnus,et al. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. , 1985, American journal of human genetics.
[32] A. Bloom. Haemostasis and thrombosis , 1981 .
[33] H. Clink,et al. Letter: Quality and quantity of survival in acute myeloid leukaemia. , 1975, Lancet.
[34] Oxon Dm. Obituary. Rupert Samuel Bruce Pearson. , 1974 .
[35] A. Clauss,et al. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .